Verve Therapeutics (VERV) IPO Opens 58% Higher

June 17, 2021 12:34 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Today's IPO for Verve Therapeutics (NASDAQ: VERV) opened for trading at $30 after pricing 14,035,789 shares of its common stock at a price to the public of $19.00 per share.

J.P. Morgan, Jefferies, Guggenheim Securities and William Blair are acting as joint book-running managers for the offering.

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Hot IPOs, IPOs, Momentum Movers, Trader Talk

Related Entities

William Blair, JPMorgan, Jefferies & Co, IPO, Guggenheim